GLP-1 microdosing is when people take smaller doses of GLP-1 drugs than are typically prescribed or FDA-recommended, often ...

On June 16, 2026, the US Food and Drug Administration (FDA) issued 25 warning letters to various telehealth companies alleging that their ...

FDA revamps peptide panel by appointing wellness clinic physicians to advise on pharmacy compounding of seven peptides, including BPC-157 and TB-500.

The Food and Drug Administration is meeting next month to consider easing restrictions on several peptides, a group of ...

The new-age pharmaceutical landscape shows a growing reliance on customized, specialized therapies known to customers as compounded medicines. Compounding occurs when an approved and licensed ...

Patricia Louis is a content editor and social media strategist with a strong background in journalism, public relations and business. As the organic social media editor, she oversees and develops ...

FDA proposes excluding blockbuster weight-loss drugs from 503B compounding list Move could limit bulk production by outsourcing facilities Novo and Lilly support FDA stance If finalized, the move ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The Food and Drug Administration is taking the first step toward potentially allowing compounding pharmacies to produce seven peptides that are currently restricted because of the agency’s previous ...

A mystery drug has shown promise for Parkinson’s disease, improving the mobility and balance of mice with Parkinson’s-like symptoms. The drug works by boosting the brain’s waste disposal system to ...

Drugmaker Eli Lilly says some copycat versions of its GLP-1 medications pose unique safety concerns — here’s what you need to know. A new study funded by Eli Lilly found that mixing compounded ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. as drugmakers and the FDA alike seek to crack down on the ...